ID   BL-41
AC   CVCL_1087
SY   BL41; BL 41; BL 041; IARC/BL41; IARC/BL 41; IARC-BL41; IARC BL41; IARC-BL-41; IARC BL 41
DR   BTO; BTO:0003854
DR   CLO; CLO_0001987
DR   CLDB; cl459
DR   ArrayExpress; E-MTAB-783
DR   ArrayExpress; E-MTAB-2770
DR   ArrayExpress; E-MTAB-3610
DR   BioSample; SAMN03473420
DR   BioSample; SAMN10987706
DR   cancercelllines; CVCL_1087
DR   Cell_Model_Passport; SIDM00985
DR   ChEMBL-Cells; CHEMBL3308526
DR   ChEMBL-Targets; CHEMBL2366173
DR   Cosmic; 910706
DR   Cosmic; 931099
DR   Cosmic; 991550
DR   Cosmic; 1086324
DR   Cosmic; 1818339
DR   Cosmic; 2297031
DR   Cosmic; 2361383
DR   Cosmic; 2814533
DR   Cosmic-CLP; 910706
DR   DepMap; ACH-000245
DR   DSMZ; ACC-160
DR   DSMZCellDive; ACC-160
DR   EGA; EGAS00001000978
DR   GDSC; 910706
DR   GEO; GSM119535
DR   GEO; GSM862863
DR   GEO; GSM862864
DR   GEO; GSM862865
DR   GEO; GSM862866
DR   GEO; GSM886889
DR   GEO; GSM887954
DR   GEO; GSM1669625
DR   GEO; GSM3150241
DR   IARC_TP53; 700
DR   IARC_TP53; 21194
DR   LiGeA; CCLE_122
DR   LINCS_LDP; LCL-2028
DR   NCBI_Iran; C493
DR   PharmacoDB; BL41_103_2019
DR   PRIDE; PXD012087
DR   PRIDE; PXD030304
DR   Progenetix; CVCL_1087
DR   PubChem_Cell_line; CVCL_1087
DR   Wikidata; Q54797155
RX   PubMed=1915267;
RX   PubMed=2645221;
RX   PubMed=2825176;
RX   PubMed=3026973;
RX   PubMed=3027441;
RX   PubMed=3037521;
RX   PubMed=3905596;
RX   PubMed=3934070;
RX   PubMed=6592381;
RX   PubMed=8547074;
RX   PubMed=8558920;
RX   PubMed=9192833;
RX   PubMed=9473234;
RX   PubMed=9973220;
RX   PubMed=11793449;
RX   PubMed=16960149;
RX   PubMed=19358282;
RX   PubMed=20164919;
RX   PubMed=22460905;
RX   PubMed=22885699;
RX   PubMed=24590883;
RX   PubMed=25355872;
RX   PubMed=25960936;
RX   PubMed=26589293;
RX   PubMed=27397505;
RX   PubMed=28196595;
RX   PubMed=30285677;
RX   PubMed=30629668;
RX   PubMed=30894373;
RX   PubMed=31068700;
RX   PubMed=35839778;
WW   https://tcpaportal.org/mclp/
CC   Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
CC   Part of: COSMIC cell lines project.
CC   Part of: MD Anderson Cell Lines Project.
CC   From: International Agency of Research on Cancer (IARC); Lyon; France.
CC   Population: Caucasian.
CC   Virology: EBV-negative.
CC   Doubling time: ~30 hours (DSMZ=ACC-160).
CC   HLA typing: A*11:01,32:01; B*35:01,49:01; C*04:01,07:01; DQA1*01:01,01:01; DQB1*05:03,05:03; DRB1*01:01,14:01 (PubMed=25960936).
CC   HLA typing: A*32:01,32:01; B*35:01,49:01; C*04:01,07:06; DQA1*01:01,01:01; DQB1*05:03,05:03; DRB1*01:01,14:01 (PubMed=26589293).
CC   Microsatellite instability: Stable (MSS) (Sanger).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Gln (c.743G>A); ClinVar=VCV000012356; Zygosity=Unspecified (PubMed=1915267).
CC   Omics: Array-based CGH.
CC   Omics: Deep exome analysis.
CC   Omics: Deep quantitative proteome analysis.
CC   Omics: DNA methylation analysis.
CC   Omics: Protein expression by reverse-phase protein arrays.
CC   Omics: SNP array analysis.
CC   Omics: Transcriptome analysis by microarray.
CC   Omics: Transcriptome analysis by RNAseq.
CC   Omics: Virome analysis using RNAseq.
CC   Genome ancestry: African=0.05%; Native American=0.06%; East Asian, North=0%; East Asian, South=0.52%; South Asian=1.34%; European, North=57.31%; European, South=40.71% (PubMed=30894373).
ST   Source(s): Cosmic-CLP; DSMZ
ST   Amelogenin: X,Y
ST   CSF1PO: 10,11 (Cosmic-CLP)
ST   CSF1PO: 9,10,11,14 (DSMZ)
ST   D13S317: 8,11
ST   D16S539: 12
ST   D18S51: 15,19
ST   D19S433: 14,16
ST   D21S11: 31.2
ST   D2S1338: 17,21
ST   D3S1358: 15,18
ST   D5S818: 11,13
ST   D7S820: 9,11
ST   D8S1179: 12,14
ST   FGA: 24
ST   Penta D: 11,12
ST   Penta E: 11,12
ST   TH01: 7,9.3
ST   TPOX: 7,8
ST   vWA: 14,18
DI   NCIt; C2912; Burkitt lymphoma
DI   ORDO; Orphanet_543; Burkitt lymphoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
OI   CVCL_IV22 ! IARC-171
SX   Male
AG   8Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 05-10-23; Version: 39
//
RX   PubMed=1915267; DOI=10.1002/j.1460-2075.1991.tb07837.x;
RA   Farrell P.J., Allan G.J., Shanahan F., Vousden K.H., Crook T.;
RT   "p53 is frequently mutated in Burkitt's lymphoma cell lines.";
RL   EMBO J. 10:2879-2887(1991).
//
RX   PubMed=2645221; DOI=10.1002/ijc.2910430219;
RA   Torsteinsdottir S., Andersson M.L., Avila-Carino J.,
RA   Ehlin-Henriksson B., Masucci M.G., Klein G., Klein E.;
RT   "Reversion of tumorigenicity and decreased agarose clonability after
RT   EBV conversion of an IgH/myc translocation-carrying BL line.";
RL   Int. J. Cancer 43:273-278(1989).
//
RX   PubMed=2825176; DOI=10.1073/pnas.84.22.8060;
RA   Calender A., Billaud M., Aubry J.-P., Banchereau J., Vuillaume M.,
RA   Lenoir G.M.;
RT   "Epstein-Barr virus (EBV) induces expression of B-cell activation
RT   markers on in vitro infection of EBV-negative B-lymphoma cells.";
RL   Proc. Natl. Acad. Sci. U.S.A. 84:8060-8064(1987).
//
RX   PubMed=3026973; DOI=10.1002/ijc.2910390215;
RA   Ehlin-Henriksson B., Manneborg-Sandlund A., Klein G.;
RT   "Expression of B-cell-specific markers in different Burkitt lymphoma
RT   subgroups.";
RL   Int. J. Cancer 39:211-218(1987).
//
RX   PubMed=3027441; DOI=10.1093/jnci/78.2.235;
RA   Cohen J.H.M., Revillard J.-P., Magaud J.-P., Lenoir G.M., Vuillaume M.,
RA   Manel A.-M., Vincent C., Bryon P.-A.;
RT   "B-cell maturation stages of Burkitt's lymphoma cell lines according
RT   to Epstein-Barr virus status and type of chromosome translocation.";
RL   J. Natl. Cancer Inst. 78:235-242(1987).
//
RX   PubMed=3037521; DOI=10.1073/pnas.84.13.4567;
RA   Masucci M.G., Torsteinsdottir S., Colombani J., Brautbar C., Klein E.,
RA   Klein G.;
RT   "Down-regulation of class I HLA antigens and of the Epstein-Barr
RT   virus-encoded latent membrane protein in Burkitt lymphoma lines.";
RL   Proc. Natl. Acad. Sci. U.S.A. 84:4567-4571(1987).
//
RX   PubMed=3905596;
RA   Favrot M.-C., Philip I., Philip T., Cabrillat H., Pinatel C.,
RA   Dore J.-F., Lenoir G.M.;
RT   "Immunophenotypic classification of 28 Burkitt cell lines with
RT   monoclonal antibodies and reagent selection for bone-marrow purging.";
RL   IARC Sci. Publ. 60:447-452(1985).
//
RX   PubMed=3934070;
RA   Lenoir G.M., Vuillaume M., Bonnardel C.;
RT   "The use of lymphomatous and lymphoblastoid cell lines in the study of
RT   Burkitt's lymphoma.";
RL   IARC Sci. Publ. 60:309-318(1985).
//
RX   PubMed=6592381; DOI=10.1093/jnci/73.4.841;
RA   Favrot M.-C., Philip I., Philip T., Portoukalian J., Dore J.-F.,
RA   Lenoir G.M.;
RT   "Distinct reactivity of Burkitt's lymphoma cell lines with eight
RT   monoclonal antibodies correlated with the ethnic origin.";
RL   J. Natl. Cancer Inst. 73:841-847(1984).
//
RX   PubMed=8547074; DOI=10.1111/j.1365-2141.1995.tb05302.x;
RA   Siebert R., Willers C.P., Schramm A., Fossa A., Dresen I.M.G.,
RA   Uppenkamp M., Nowrousian M.R., Seeber S., Opalka B.;
RT   "Homozygous loss of the MTS1/p16 and MTS2/p15 genes in lymphoma and
RT   lymphoblastic leukaemia cell lines.";
RL   Br. J. Haematol. 91:350-354(1995).
//
RX   PubMed=8558920;
RA   Dirks W.G., Zaborski M., Jager K., Challier C., Shiota M.,
RA   Quentmeier H., Drexler H.G.;
RT   "The (2;5)(p23;q35) translocation in cell lines derived from malignant
RT   lymphomas: absence of t(2;5) in Hodgkin-analogous cell lines.";
RL   Leukemia 10:142-149(1996).
//
RX   PubMed=9192833;
RA   Cherney B.W., Bhatia K.G., Sgadari C., Gutierrez M.I., Mostowski H.S.,
RA   Pike S.E., Gupta G., Magrath I.T., Tosato G.;
RT   "Role of the p53 tumor suppressor gene in the tumorigenicity of
RT   Burkitt's lymphoma cells.";
RL   Cancer Res. 57:2508-2515(1997).
//
RX   PubMed=9473234; DOI=10.1182/blood.V91.5.1680;
RA   Klangby U., Okan I., Magnusson K.P., Wendland M., Lind P., Wiman K.G.;
RT   "p16/INK4a and p15/INK4b gene methylation and absence of p16/INK4a
RT   mRNA and protein expression in Burkitt's lymphoma.";
RL   Blood 91:1680-1687(1998).
//
RX   PubMed=9973220;
RA   Gutierrez M.I., Cherney B.W., Hussain A., Mostowski H.S., Tosato G.,
RA   Magrath I.T., Bhatia K.G.;
RT   "Bax is frequently compromised in Burkitt's lymphomas with
RT   irreversible resistance to Fas-induced apoptosis.";
RL   Cancer Res. 59:696-703(1999).
//
RX   PubMed=11793449; DOI=10.1002/gcc.10022;
RA   Sobol H., Benziane A., Kerangueven F., Yin L., Noguchi T., Pauly S.,
RA   Eisinger F., Longy M., Romeo G., Lenoir G.M., Birnbaum D.;
RT   "Genome-wide search for loss of heterozygosity in Burkitt lymphoma
RT   cell lines.";
RL   Genes Chromosomes Cancer 33:217-224(2002).
//
RX   PubMed=16960149; DOI=10.1182/blood-2006-06-026500;
RA   Mestre-Escorihuela C., Rubio-Moscardo F., Richter J.A., Siebert R.,
RA   Climent J., Fresquet V., Beltran E., Agirre X., Marugan I., Marin M.,
RA   Rosenwald A., Sugimoto K.-j., Wheat L.M., Karran E.L., Garcia J.F.,
RA   Sanchez-Verde L., Prosper F., Staudt L.M., Pinkel D., Dyer M.J.S.,
RA   Martinez-Climent J.A.;
RT   "Homozygous deletions localize novel tumor suppressor genes in B-cell
RT   lymphomas.";
RL   Blood 109:271-280(2007).
//
RX   PubMed=19358282; DOI=10.1002/ijc.24351;
RA   Inagaki A., Ishida T., Yano H., Ishii T., Kusumoto S., Ito A., Ri M.,
RA   Mori F., Ding J.-M., Komatsu H., Iida S., Ueda R.;
RT   "Expression of the ULBP ligands for NKG2D by B-NHL cells plays an
RT   important role in determining their susceptibility to
RT   rituximab-induced ADCC.";
RL   Int. J. Cancer 125:212-221(2009).
//
RX   PubMed=20164919; DOI=10.1038/nature08768;
RA   Bignell G.R., Greenman C.D., Davies H., Butler A.P., Edkins S.,
RA   Andrews J.M., Buck G., Chen L., Beare D., Latimer C., Widaa S.,
RA   Hinton J., Fahey C., Fu B.-Y., Swamy S., Dalgliesh G.L., Teh B.T.,
RA   Deloukas P., Yang F.-T., Campbell P.J., Futreal P.A., Stratton M.R.;
RT   "Signatures of mutation and selection in the cancer genome.";
RL   Nature 463:893-898(2010).
//
RX   PubMed=22460905; DOI=10.1038/nature11003;
RA   Barretina J.G., Caponigro G., Stransky N., Venkatesan K., Margolin A.A.,
RA   Kim S., Wilson C.J., Lehar J., Kryukov G.V., Sonkin D., Reddy A.,
RA   Liu M., Murray L., Berger M.F., Monahan J.E., Morais P., Meltzer J.,
RA   Korejwa A., Jane-Valbuena J., Mapa F.A., Thibault J., Bric-Furlong E.,
RA   Raman P., Shipway A., Engels I.H., Cheng J., Yu G.-Y.K., Yu J.-J.,
RA   Aspesi P. Jr., de Silva M., Jagtap K., Jones M.D., Wang L., Hatton C.,
RA   Palescandolo E., Gupta S., Mahan S., Sougnez C., Onofrio R.C.,
RA   Liefeld T., MacConaill L.E., Winckler W., Reich M., Li N.-X., Mesirov J.P.,
RA   Gabriel S.B., Getz G., Ardlie K., Chan V., Myer V.E., Weber B.L.,
RA   Porter J., Warmuth M., Finan P., Harris J.L., Meyerson M.L., Golub T.R.,
RA   Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.;
RT   "The Cancer Cell Line Encyclopedia enables predictive modelling of
RT   anticancer drug sensitivity.";
RL   Nature 483:603-607(2012).
//
RX   PubMed=22885699; DOI=10.1038/nature11378;
RA   Schmitz R., Young R.M., Ceribelli M., Jhavar S., Xiao W.-M., Zhang M.-L.,
RA   Wright G., Shaffer A.L. III, Hodson D.J., Buras E., Liu X.-L., Powell J.I.,
RA   Yang Y.-D., Xu W.-H., Zhao H., Kohlhammer H., Rosenwald A., Kluin P.,
RA   Muller-Hermelink H.-K., Ott G., Gascoyne R.D., Connors J.M.,
RA   Rimsza L.M., Campo E., Jaffe E.S., Delabie J., Smeland E.B.,
RA   Ogwang M.D., Reynolds S.J., Fisher R.I., Braziel R.M., Tubbs R.R.,
RA   Cook J.R., Weisenburger D.D., Chan W.C., Pittaluga S., Wilson W.,
RA   Waldmann T.A., Rowe M., Mbulaiteye S.M., Rickinson A.B., Staudt L.M.;
RT   "Burkitt lymphoma pathogenesis and therapeutic targets from structural
RT   and functional genomics.";
RL   Nature 490:116-120(2012).
//
RX   PubMed=24590883; DOI=10.1002/gcc.22161;
RA   Murga Penas E.-M., Schilling G., Behrmann P., Klokow M.,
RA   Vettorazzi E., Bokemeyer C., Dierlamm J.;
RT   "Comprehensive cytogenetic and molecular cytogenetic analysis of 44
RT   Burkitt lymphoma cell lines: secondary chromosomal changes
RT   characterization, karyotypic evolution, and comparison with primary
RT   samples.";
RL   Genes Chromosomes Cancer 53:497-515(2014).
//
RX   PubMed=25355872; DOI=10.1128/JVI.02570-14;
RA   Cao S.-B., Strong M.J., Wang X., Moss W.N., Concha M., Lin Z.,
RA   O'Grady T., Baddoo M., Fewell C., Renne R., Flemington E.K.;
RT   "High-throughput RNA sequencing-based virome analysis of 50 lymphoma
RT   cell lines from the Cancer Cell Line Encyclopedia project.";
RL   J. Virol. 89:713-729(2015).
//
RX   PubMed=25960936; DOI=10.4161/21624011.2014.954893;
RA   Boegel S., Lower M., Bukur T., Sahin U., Castle J.C.;
RT   "A catalog of HLA type, HLA expression, and neo-epitope candidates in
RT   human cancer cell lines.";
RL   OncoImmunology 3:e954893.1-e954893.12(2014).
//
RX   PubMed=26589293; DOI=10.1186/s13073-015-0240-5;
RA   Scholtalbers J., Boegel S., Bukur T., Byl M., Goerges S., Sorn P.,
RA   Loewer M., Sahin U., Castle J.C.;
RT   "TCLP: an online cancer cell line catalogue integrating HLA type,
RT   predicted neo-epitopes, virus and gene expression.";
RL   Genome Med. 7:118.1-118.7(2015).
//
RX   PubMed=27397505; DOI=10.1016/j.cell.2016.06.017;
RA   Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P.,
RA   Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H.,
RA   Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H.,
RA   Deng X.-M., Egan R.K., Liu Q.-S., Mironenko T., Mitropoulos X.,
RA   Richardson L., Wang J.-H., Zhang T.-H., Moran S., Sayols S.,
RA   Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P.,
RA   Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H.,
RA   Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.;
RT   "A landscape of pharmacogenomic interactions in cancer.";
RL   Cell 166:740-754(2016).
//
RX   PubMed=28196595; DOI=10.1016/j.ccell.2017.01.005;
RA   Li J., Zhao W., Akbani R., Liu W.-B., Ju Z.-L., Ling S.-Y., Vellano C.P.,
RA   Roebuck P., Yu Q.-H., Eterovic A.K., Byers L.A., Davies M.A., Deng W.-L.,
RA   Gopal Y.N.V., Chen G., von Euw E.M., Slamon D.J., Conklin D.,
RA   Heymach J.V., Gazdar A.F., Minna J.D., Myers J.N., Lu Y.-L., Mills G.B.,
RA   Liang H.;
RT   "Characterization of human cancer cell lines by reverse-phase protein
RT   arrays.";
RL   Cancer Cell 31:225-239(2017).
//
RX   PubMed=30285677; DOI=10.1186/s12885-018-4840-5;
RA   Tan K.-T., Ding L.-W., Sun Q.-Y., Lao Z.-T., Chien W., Ren X.,
RA   Xiao J.-F., Loh X.-Y., Xu L., Lill M., Mayakonda A., Lin D.-C., Yang H.,
RA   Koeffler H.P.;
RT   "Profiling the B/T cell receptor repertoire of lymphocyte derived cell
RT   lines.";
RL   BMC Cancer 18:940.1-940.13(2018).
//
RX   PubMed=30629668; DOI=10.1371/journal.pone.0210404;
RA   Uphoff C.C., Pommerenke C., Denkmann S.A., Drexler H.G.;
RT   "Screening human cell lines for viral infections applying RNA-Seq data
RT   analysis.";
RL   PLoS ONE 14:E0210404-E0210404(2019).
//
RX   PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747;
RA   Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.;
RT   "An interactive resource to probe genetic diversity and estimated
RT   ancestry in cancer cell lines.";
RL   Cancer Res. 79:1263-1273(2019).
//
RX   PubMed=31068700; DOI=10.1038/s41586-019-1186-3;
RA   Ghandi M., Huang F.W., Jane-Valbuena J., Kryukov G.V., Lo C.C.,
RA   McDonald E.R. III, Barretina J.G., Gelfand E.T., Bielski C.M., Li H.-X.,
RA   Hu K., Andreev-Drakhlin A.Y., Kim J., Hess J.M., Haas B.J., Aguet F.,
RA   Weir B.A., Rothberg M.V., Paolella B.R., Lawrence M.S., Akbani R.,
RA   Lu Y.-L., Tiv H.L., Gokhale P.C., de Weck A., Mansour A.A., Oh C.,
RA   Shih J., Hadi K., Rosen Y., Bistline J., Venkatesan K., Reddy A.,
RA   Sonkin D., Liu M., Lehar J., Korn J.M., Porter D.A., Jones M.D.,
RA   Golji J., Caponigro G., Taylor J.E., Dunning C.M., Creech A.L.,
RA   Warren A.C., McFarland J.M., Zamanighomi M., Kauffmann A.,
RA   Stransky N., Imielinski M., Maruvka Y.E., Cherniack A.D.,
RA   Tsherniak A., Vazquez F., Jaffe J.D., Lane A.A., Weinstock D.M.,
RA   Johannessen C.M., Morrissey M.P., Stegmeier F., Schlegel R.,
RA   Hahn W.C., Getz G., Mills G.B., Boehm J.S., Golub T.R., Garraway L.A.,
RA   Sellers W.R.;
RT   "Next-generation characterization of the Cancer Cell Line
RT   Encyclopedia.";
RL   Nature 569:503-508(2019).
//
RX   PubMed=35839778; DOI=10.1016/j.ccell.2022.06.010;
RA   Goncalves E., Poulos R.C., Cai Z.-X., Barthorpe S., Manda S.S., Lucas N.,
RA   Beck A., Bucio-Noble D., Dausmann M., Hall C., Hecker M., Koh J.,
RA   Lightfoot H., Mahboob S., Mali I., Morris J., Richardson L.,
RA   Seneviratne A.J., Shepherd R., Sykes E., Thomas F., Valentini S.,
RA   Williams S.G., Wu Y.-X., Xavier D., MacKenzie K.L., Hains P.G., Tully B.,
RA   Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.;
RT   "Pan-cancer proteomic map of 949 human cell lines.";
RL   Cancer Cell 40:835-849.e8(2022).
//